Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
174 hedge funds and large institutions have $1.4B invested in Dicerna Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 67 reducing their positions, and 26 closing their positions.
28% more capital invested
Capital invested by funds: $1.1B → $1.4B (+$303M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1% more funds holding
Funds holding: 172 → 174 (+2)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
16% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 67
48% less call options, than puts
Call options by funds: $2.5M | Put options by funds: $4.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$52.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$24.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$19.5M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$10.8M |
| 5 |
Goldman Sachs
New York
|
+$8.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$22M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.7M |
| 3 |
Renaissance Technologies
New York
|
-$10.2M |
| 4 |
BM
Bridger Management
New York
|
-$9.05M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.03M |
DRNA Hedge Fund Activity: Q4 2020 in Review
174 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2020, worth a combined $1.4B — up 28% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new DRNA positions and 26 closed out — a net gain of 2 holders — while 56 added to existing stakes and 67 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $52.1M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $22M.
- 174 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2020, up from 172 in Q3 2020.
- Funds reported $1.4B of Dicerna Pharmaceuticals, Inc. stock for Q4 2020, up 28% quarter-over-quarter.
- 28 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2020 and 26 closed out, a net change of +2 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2020 was Point72 Asset Management, an estimated $52.1M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2020 was Bain Capital Life Sciences Investors, an estimated $22M sold.
Based on aggregated 13F filings for Q4 2020.